Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Apomorphine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    40 result(s) found for: Apomorphine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-003456-70 Sponsor Protocol Number: CTH-302 Start Date*: 2017-03-22
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated ...
    Medical condition: Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations ("OFF episodes")
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10034006 Parkinson's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003144-23 Sponsor Protocol Number: 2017/81 Start Date*: 2018-09-05
    Sponsor Name:University of Liège
    Full Title: Treating severe brain-injured patients with apomorphine : a behavioural and neuroimaging study
    Medical condition: Disorders of consciousness
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003315-60 Sponsor Protocol Number: A201 Start Date*: 2020-11-10
    Sponsor Name:Criceto IKM B.V.
    Full Title: A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON®) in subjects with Parkinson's Disease
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000657-36 Sponsor Protocol Number: 46934 Start Date*: 2015-06-22
    Sponsor Name:University Medical Center Groningen
    Full Title: Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000980-10 Sponsor Protocol Number: CT-37527-13-0124 Start Date*: 2013-10-18
    Sponsor Name:Britannia Pharmaceuticals Limited
    Full Title: TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson’s disease patients with mo...
    Medical condition: Parkinson Disease (PD) in patients with motor fluctuations not well controlled on medical treatment
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10034006 Parkinson's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed) FR (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000636-18 Sponsor Protocol Number: CTH-300 Start Date*: 2016-05-12
    Sponsor Name:Sunuvion Pharmaceuticals Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease...
    Medical condition: Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10034006 Parkinson's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004447-11 Sponsor Protocol Number: VR040/2/008 Start Date*: Information not available in EudraCT
    Sponsor Name:Vectura Limited
    Full Title: A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effe...
    Medical condition: Unpredictable motor fluctuation or “On-Off” or “Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    11 10067209 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000637-43 Sponsor Protocol Number: CTH-301 Start Date*: 2016-05-12
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF...
    Medical condition: "Levodopa Responsive Patients with Parkinson’s Disease complicated by Motor Fluctuations (“OFF” Episodes)"
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10034006 Parkinson's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Ongoing) AT (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000102-11 Sponsor Protocol Number: NL55949 Start Date*: 2016-11-23
    Sponsor Name:University Medical Center Groningen
    Full Title: Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations.
    Medical condition: Parkinson's disease patients with refractory visual hallucinations
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001453-31 Sponsor Protocol Number: CONMED3 Start Date*: Information not available in EudraCT
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: Automated pupillometry and NIRS-EEG to detect signatures of consciousness in acute brain injury after apomorphine and methylphenidate stimulation: A placebo-controlled, randomized, cross-over study
    Medical condition: We investigate the possible effects of commercially available apomorphine and methylphenidate on signatures of consciousness in patients admitted to the ICU with acute disorder of consciousness, us...
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029205 - Nervous system disorders 10013509 Disturbances in consciousness NEC HLT
    21.1 10029205 - Nervous system disorders 10067967 Brain injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001762-29 Sponsor Protocol Number: CTH-201 Start Date*: 2016-11-08
    Sponsor Name:SUNOVION PHARMACEUTICALS
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuatio...
    Medical condition: Parkinson's Disease (PD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000826-89 Sponsor Protocol Number: 35RC21_9909_PHARM-APO Start Date*: 2021-04-23
    Sponsor Name:CHU Rennes
    Full Title: Etude pharmacocinétique de l’apomorphine en perfusion sous-cutanée continue diurne chez le patient parkinsonien équilibré sous traitement
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000391-32 Sponsor Protocol Number: 20102D05 Start Date*: 2006-06-06
    Sponsor Name:Britannia Pharmaceuticals Limited
    Full Title: A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, ...
    Medical condition: Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005509-79 Sponsor Protocol Number: VR040/2/003 Start Date*: 2006-12-21
    Sponsor Name:Vectura Group plc
    Full Title: A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patient...
    Medical condition: Idiopathic Parkinson's Disease patients who have motor fluctuations with recognisable motor “off” periods
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005120-13 Sponsor Protocol Number: VR040/001 Start Date*: 2005-12-21
    Sponsor Name:Vectura Group plc
    Full Title: A clinic based, Phase IIa, randomised, double-blind, placebo-controlled, ascending dose, single centre study investigating the safety, tolerability, efficacy, and pharmacokinetics of VR040 in patie...
    Medical condition: Hypomobility (“off” or “freezing”) episodes associated with advanced Parkinson’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006045-10 Sponsor Protocol Number: loc/08-08VerinAPOTEP Start Date*: 2009-02-06
    Sponsor Name:CHU de Rennes
    Full Title: Effet de la stimulation dopaminergique continue par pompe à apomorphine sur les fluctuations cognitives et psychiques des patients parkinsoniens: étude clinique et métabolique cérébrale par TEP au ...
    Medical condition: L’objectif thérapeutique principal dans la maladie de Parkinson est de contrôler les fluctuations motrices. Cependant des fluctuations non motrices (FNM) sont fréquemment observées et semblent corr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002454-20 Sponsor Protocol Number: 35RC15_9724 Start Date*: 2016-10-17
    Sponsor Name:CHU de Rennes
    Full Title: Apomorphine Pump in Early Stage of Parkinson’s Disease
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002010-38 Sponsor Protocol Number: SC3-90049-001 Start Date*: 2005-11-21
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson D...
    Medical condition: Advanced Parkinson´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006721-27 Sponsor Protocol Number: CERE-120-06 Start Date*: 2008-10-20
    Sponsor Name:Ceregene Inc.
    Full Title: A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2...
    Medical condition: idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005814-31 Sponsor Protocol Number: ND0612H-012 Start Date*: 2016-08-29
    Sponsor Name:NeuroDerm Ltd.
    Full Title: A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkin...
    Medical condition: Subjects with advanced Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) DE (Ongoing) CZ (Completed) PL (Ongoing) HU (Ongoing) ES (Completed) BE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:38:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA